New technologies and directed agents for applications of cancer imaging

Journal of Clinical Oncology

Volumn 24, Issue 20, 2006, Pages 3299-3308

  Atri, Mostafa ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IRON OXIDE; RADIOLIGAND; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOPPLER ECHOGRAPHY; GENE TARGETING; HUMAN; LONGITUDINAL STUDY; MEDICAL INFORMATION; MEDICAL INSTRUMENTATION; METASTASIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TISSUE SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; DRUG DELIVERY SYSTEM; ECHOGRAPHY; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 33745938246     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6159     Document Type: Review

References (94)

1. Floyd E, McShane TM: Development and use of biomarkers in oncology drug development. Toxicol Pathol 32:106-115, 2004
2. Kitano H: Systems biology: A brief overview. Science 295:1662-1664, 2002
3. Weissleder R, Mahmood U: Molecular imaging. Radiology 219:316-333, 2001
4. Norris DG: High field human imaging. J Magn Reson Imaging 18:519-529, 2003
5. Johnson GA, Cofer GP, Gewalt SL, et al: Morphologic phenotyping with MR microscopy: The visible mouse. Radiology 222:789-793, 2002
6. Tatum JL, Hoffman JM: Congressional update: Report from the Biomedical Imaging Program of the National Cancer Institute - Imaging drug development. Acad Radiol 7:1007-1008, 2000
7. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
8. Boehm T, Folkman J, Browder T, et al: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
9. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
10. Hohenester E, Sasaki T, Olsen BR, et al: Crystal structure of the angiogenesis inhibitor endostatin at 1.5: A resolution. Embo J 17:1656-1664, 1998
11. Los M, Voest EE: The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 28:93-105, 2001
12. Halfter W, Dong S, Schurer B, et al: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273:25404-25412, 1998
13. Dhanabal M, Volk R, Ramchandran R, et al: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 258: 345-352, 1999
14. Weidner N: Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 184:119-122, 1998
15. Rak JW, St Croix BD, Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6:3-18, 1995
16. Haroon ZA, Peters KG, Greenberg CS, et al: Angiogenesis and oxygen transport in solid tumors. In: Teicher B (ed): Antiangiogenic agents in cancer therapy. Totowa, NJ, Humana Press Inc, 1999, pp 3-21
17. Neufeld G, Cohen T, Gengrinovitch S, et al: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13:9-22, 1999
18. Gilles R, Zafrani B, Guinebretiere JM, et al: Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 196:415419, 1995
19. Bose S, Lesser ML, Norton L, et al: Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 120:81-85, 1996
20. Gasparini G, Toi M, Miceli R, et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with nodepositive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5:101-111, 1999
21. Obermair A, Kucera E, Mayerhofer K, et al: Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. Int J Cancer 74:455-458, 1997
22. Linderholm B, Tavelin B, Grankvist K, et al: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128, 1998
23. Thorpe PE, Chaplin DJ, Blakey DC: The first international conference on vascular targeting: Meeting overview. Cancer Res 63:1144-1147, 2003
24. Mullani N, Herbst R, Abbruzzese J, et al: 9:00-09:15: Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clin Positron Imaging 3:151, 2000
25. Padhani AR, Husband JE: Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56:607-620, 2001
26. Rak JW, Yuh WT, Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6:3-18, 1996
27. Buckley DL, Drew PJ, Mussurakis S, et al: Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 7:461464, 1997
28. Hulka CA, Edmister WB, Smith BL, et al: Dynamic echo-planar imaging of the breast: Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837-842, 1997
29. Cooper RA, Carrington BM, Loncaster JA, et al: Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53-59, 2000
30. Knopp MV, Weiss E, Sinn HP, et al: Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266, 1999
31. Pham CD, Roberts TP, van Bruggen N, et al: Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225-230, 1998
32. Padhani AR: Tumor perfusion studies in human tumours. Br J Radiol 72:427-431, 1999
33. Kuhl CK, Mielcareck P, Klaschik S, et al: Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101-110, 1999
34. Parker GJ, Suckling J, Tanner SF, et al: Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7:564-574, 1997
35. Padhani AR, MacVicar AD, Gapinski CJ, et al: Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 218:365-374, 2001
36. Tofts PS: Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91-101, 1997
37. Flickinger FW, Allison JD, Sherry RM, et al: Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 11:617-620, 1993
38. Kaiser WA, Zeitler E: MR imaging of the breast: Fast imaging sequences with and without Gd-DTPA - Preliminary observations. Radiology 170: 681-686, 1989
39. Boetes C, Barentsz JO, Mus RD, et al: MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 193:777-781, 1994
40. Gilles R, Guinebretiere JM, Shapeero LG, et al: Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: Preliminary results in 26 patients. Radiology 188:473-478, 1993
41. Brinck U, Fischer U, Korabiowska M, et al: The variability of fibroadenoma in contrast-enhanced dynamic MR mammography. AJR Am J Roentgenol 168:1331-1334, 1997
42. Padhani AR, Gapinski CJ, Macvicar DA, et al: Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55:99-109, 2000
43. Barentsz JO, Engelbrecht M, Jager GJ, et al: Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295-304, 1999
44. Reddick WE, Taylor JS, Fletcher BD: Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10:277-285, 1999
45. Barentsz JO, Berger-Hartog O, Witjes JA, et al: Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791-797, 1998
46. Knopp MV, Brix G, Junkermann HJ, et al: MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 2:633-658, 1994
47. Mayr NA, Yuh WT, Arnholt JC, et al: Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12:1027-1033, 2000
48. de Vries A, Griebel J, Kremser C, et al: Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: Preliminary results and implications for therapy. Radiology 217:385-391, 2000
49. Hawighorst H, Weikel W, Knapstein PG, et al: Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305-2312, 1998
50. Mayr NA, Yuh WT, Magnotta VA, et al: Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 36:623-633, 1996
51. Herbst RS, Mullani NA, Davis DW, et al: Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 2002
52. Bacharach SL, Libutti SK, Carrasquillo JA: Measuring tumor blood flow with H(2)(15)O: Practical considerations. Nucl Med Biol 27:671-676, 2000
53. Beaney RP, Lammertsma AA, Jones T, et al: Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1:131-134, 1984
54. Rhodes CG, Wise RJ, Gibbs JM, et al: In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14:614-626, 1983
55. Ito M, Lammertsma AA, Wise RJ, et al: Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 150 and positron emission tomography: Analytical techniques and preliminary results. Neuroradiology 23:63-74, 1982
56. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
57. Hofstra L, Liem IH, Dumont EA, et al: Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356:209-212, 2000
58. Miles KA, Charnsangavej C, Lee FT, et al: Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840-850, 2000
59. Miles KA: Functional computed tomography in oncology. Eur J Cancer 38:2079-2084, 2002
60. Miles KA: Tumour angiogenesis and its relation to contrast enhancement on computed tomography: A review. Eur J Radiol 30:198-205, 1999
61. Gillard JH, Antoun NM, Burnet NG, et al: Reproducibility of quantitative CT perfusion imaging. Br J Radiol 74:552-555, 2001
62. Gillard JH, Minhas PS, Hayball MP, et al: Assessment of quantitative computed tomographic cerebral perfusion imaging with H2(15)O positron emission tomography. Neurol Res 22:457-464, 2000
63. Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379, 2000
64. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
65. Ferrara KW, Merritt CR, Burns PN, et al: Evaluation of tumor angiogenesis with US: Imaging, Doppler, and contrast agents. Acad Radiol 7:824-839, 2000
66. Peters-Engl C, Medl M, Mirau M, et al: Color-coded and spectral Doppler flow in breast carcinomas: Relationship with the tumor microvasculature. Breast Cancer Res Treat 47:83-89, 1998
67. Gee MS, Saunders HM, Lee JC, et al: Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 61:2974-2982, 2001
68. Iordanescu I, Becker C, Zetter B, et al: Tumor vascularity: Evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors. Radiology 222:460-467, 2002
69. Sieswerda GT, Yang L, Boo MB, et al: Real-time perfusion imaging: A new echocardiographic technique for simultaneous evaluation of myocardial perfusion and contraction. Echocardiography 20: 545-555, 2003
70. Lanza GM, Wickline SA: Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Probl Cardiol 28:625-653, 2003
71. Weissleder R, Moore A, Mahmood U, et al: In vivo magnetic resonance imaging of transgene expression. Nat Med 6:351-355, 2000
72. Weissleder R, Elizondo G, Wittenberg J, et al: Ultrasmall superparamagnetic iron oxide: An intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175:494498, 1990
73. Stets C, Brandt S, Wallis F, et al: Axillary lymph node metastases: A statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 16:60-68, 2002
74. Michel SC, Keller TM, Frohlich JM, et al: Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225:527-536, 2002
75. Pannu HK, Wang KP, Borman TL, et al: MR imaging of mediastinal lymph nodes: Evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 12:899-904, 2000
76. Mack MG, Balzer JO, Straub R, et al: Super-paramagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 222:239-244, 2002
77. Sigal R, Vogl T, Casselman J, et al: Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall super-paramagnetic iron oxide particles (Sinerem MR) - Results of a phase-III multicenter clinical trial. Eur Radiol 12:1104-1113, 2002
78. Harisinghani MG, Barentsz J, Hahn PF, et al: Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med 348:2491-2499, 2003
79. Massoud TF, Gambhir SS: Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17:545-580, 2003
80. Li KC, Bednarski MD: Vascular-targeted molecular imaging using functionalized polymerized vesicles. J Magn Reson Imaging 16:388-393, 2002
81. Winter PM, Caruthers SD, Kassner A, et al: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63:5838-5843, 2003
82. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95, 2001
83. Lesko LJ, Atkinson AJ Jr: Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347-366, 2001
84. Beshara N, Fung Kee Fung M, Faught W: The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. Eur J Gynaecol Oncol 23:287-290, 2002
85. Seemann MD: Whole-body PET/MRI: The future in oncological imaging. Technol Cancer Res Treat 4:577-582, 2005
86. Lanza GM, Winter P, Caruthers S, et al: Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol 5:495-507, 2004
87. Shah K, Jacobs A, Breakefield XO, et al: Molecular imaging of gene therapy for cancer. Gene Ther 11:1175-1187, 2004
88. Jacobs A, Voges J, Reszka R, et al: Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358:727-729, 2001
89. Allport JR, Weissleder R: In vivo imaging of gene and cell therapies. Exp Hematol 29:1237-1246, 2001
90. Bao S, Thrall BD, Miller D: MRX 501: A novel ultrasound contrast agent with therapeutic properties. Acad Radiol 23:953-959, 1998
91. Unger EC, McCreery T, Sweitzer R, et al: MRX 501: A novel ultrasound contrast agent with therapeutic properties. Acad Radiol 5 Suppl 1:S247-S249, 1998
92. Unger EC, McCreery TP, Sweitzer RH, et al: Acoustically active lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent. Invest Radiol 33:886-892, 1998
93. Price RJ, Skyba DM, Kaul S, et al: Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 98:1264-1267, 1998
94. Bao S, Thrall BD, Miller DL: Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 23:953-959, 1997